Objective To observe Safety of bivalirudin in primary percutaneous coronary intervention (P CI) on patients with acute ST-segment elevation myocardial Infarction( STEMI) and metabolic syndrome. Methods From 2016/7 to 2017/7,a total of 92 patients with acute STEMI and metabolic syndrome treated by primary PCI in our hospital were retrospectively studied.The patients were divided in to two groups according to procedural bivalirudin application as bivalirudin group and heparin group. The baseline condition,coronary artery imaging condition,perioperative and 30-day post-operative occurrence of bleeding events and adverse cardiovascular events were compared between two groups. Results There was no significant difference in incidence of adverse cardiovascular events between two groups( P < 0.05),but the total number of cases with occurrence of bleeding events in the bivalirudin group were significant lower than the heparin group. Conclusion With advantage of lower incidence of bleeding and better safety,bivalirudin shows equivalent antithrombotic effect to heparin.
The Journal of Practical Medicine